Charisela® Technologies, Inc. Announces New HyFlo-Ig® Product Line; Begins Shipping Its No Dilution, No Wash, 45 Minute Mouse and Human IgG Flow Cytometry Assays

MENLO PARK, Calif. -- (BUSINESS WIRE) -- Charisela Technologies, Inc., a manufacturer of advanced flow cytometry assays, announced today that it has begun shipments of its next generation Human and Mouse IgG kappa and IgG lambda assays, the first products in its HyFlo-Ig product line of research use only (RUO) assays. These assays can be used in a variety of situations with hybridomas such as monoclonal antibody (mAb) therapeutics production and basic research.

The assays require no sample dilutions for concentrations up to 1mg/mL as opposed to other assays on the market that require serial dilutions from 1:1,000 to over 1:50,000. The assays have fewer components and fewer steps than competing assays. All these factors contribute to increased accuracy and substantial time savings; results are obtained in 45 minutes as opposed to several hours for the typical ELISA assay and no wash steps are required for qualitative tests and one 5 minute wash step for quantitative measurements. The assays run on all flow cytometers and are debris and doublet free. “We are very pleased to be offering assays that are simpler, faster, more accurate, and more cost effective than any other assays available today,” said Robert Danielzadeh, the Company’s founder and CTO. He added, “they are perfect for not only lab bench work, but for high throughput screening, where fewer steps and speed are important.”

“The potential applications and number of market opportunities for our assays are increasing rapidly and we are very excited to be at the leading edge of assay development,” Danielzadeh said. Currently, there are more than 30 approved monoclonal antibody therapeutics on the market and hundreds of candidate molecules in the pipeline. The development of therapeutic antibodies is a rapidly growing and well-funded field. The disease indications for antibody therapeutics are rapidly diversifying beyond the two primary areas of oncology and inflammatory diseases, as exemplified by an increasing number of clinical programs in infectious diseases, Alzheimer’s disease, metabolic diseases and cancer.

The Company will be adding 4 more assays to its HyFlo-Ig line over the next 30 days.